CLINICAL RESEARCH: LIPIDS AND CAD
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial
Michael Miller, MD, FACC*,1,*,
Christopher P. Cannon, MD, FACC ,2,
Sabina A. Murphy, MPH,
Jie Qin, MS,
Kausik K. Ray, MD, MRCP ,3,
Eugene Braunwald, MD, MACC,4 for the PROVE IT-TIMI 22 Investigators
* University of Maryland Medical Center, Baltimore, Maryland
TIMI Study Group, Brigham and Women’s Hospital, Boston, Massachusetts
University of Cambridge, Cambridge, United Kingdom.
Manuscript received August 21, 2007;
revised manuscript received October 18, 2007,
accepted October 22, 2007.
* Reprint requests and correspondence: Dr. Michael Miller, University of Maryland Hospital, Division of Cardiology, Room S3B06, 22 South Greene Street, Baltimore, Maryland 21201. (Email: mmiller{at}heart.umaryland.edu).
Objectives: The purpose of this study was to assess the impact of on-treatment triglycerides (TG) on coronary heart disease (CHD) risk after an acute coronary syndrome (ACS).
Background: The PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) 22 trial demonstrated that low-density lipoprotein cholesterol (LDL-C) <70 mg/dl was associated with greater CHD event reduction than LDL-C <100 mg/dl after ACS. However, the impact of low on-treatment TG on CHD risk beyond LDL-C <70 mg/dl has not been explored.
Methods: The PROVE IT-TIMI 22 trial evaluated 4,162 patients hospitalized for ACS and randomized to atorvastatin 80 mg or pravastatin 40 mg daily. The relationship between on-treatment levels of TG and LDL-C and the composite end point of death, myocardial infarction (MI), and recurrent ACS were assessed 30 days after initial presentation.
Results: Low on-treatment TG (<150 mg/dl) was associated with reduced CHD risk compared with higher TG in univariate analysis (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.62 to 0.87; p < 0.001) and in adjusted analysis (HR 0.80, 95% CI 0.66 to 0.97; p = 0.025). For each 10-mg/dl decrement in on-treatment TG, the incidence of death, MI, and recurrent ACS was lower by 1.6% or 1.4% after adjustment for LDL-C or non–high-density lipoprotein cholesterol and other covariates (p < 0.001 and p = 0.01, respectively). Lower CHD risk was also observed with TG <150 mg/dl and LDL-C <70 mg/dl (HR 0.72, 95% CI 0.54 to 0.94; p = 0.017) or low on-treatment TG, LDL-C, and C-reactive protein (<2 mg/l) (HR 0.59, 95% CI 0.41 to 0.83; p = 0.002) compared with higher levels of each variable in adjusted analysis.
Conclusions: On-treatment TG <150 mg/dl was independently associated with a lower risk of recurrent CHD events, lending support to the concept that achieving low TG may be an additional consideration beyond low LDL-C in patients after ACS. (The PROVE IT-TIMI 22 trial; NCT00382460
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CHD = coronary heart disease | | CRP = C-reactive protein | | HDL-C = high-density lipoprotein cholesterol | | LDL-C = low-density lipoprotein cholesterol | | MI = myocardial infarction | | TG = triglycerides |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A35-A36.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Bitzur, H. Cohen, Y. Kamari, A. Shaish, and D. Harats
Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
Diabetes Care,
November 1, 2009;
32(suppl_2):
S373 - S377.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Eur. Heart J.,
October 12, 2009;
(2009)
ehp399v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Miller
Dyslipidemia and cardiovascular risk: the importance of early prevention
QJM,
September 1, 2009;
102(9):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Leon and U. G. Bronas
Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management
American Journal of Lifestyle Medicine,
July 1, 2009;
3(4):
257 - 273.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Amarenco, L. B. Goldstein, M. Messig, B. J. O'Neill, A. Callahan III, H. Sillesen, M. G. Hennerici, J. A. Zivin, K.M.A. Welch, and on behalf of the SPARCL Investigators
Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial
Stroke,
July 1, 2009;
40(7):
2486 - 2492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice
J. Lipid Res.,
June 1, 2009;
50(6):
1090 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mora
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Circulation,
May 5, 2009;
119(17):
2396 - 2404.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. I. Pollin, C. M. Damcott, H. Shen, S. H. Ott, J. Shelton, R. B. Horenstein, W. Post, J. C. McLenithan, L. F. Bielak, P. A. Peyser, et al.
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Science,
December 12, 2008;
322(5908):
1702 - 1705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Caron and B. Staels
Apolipoprotein CIII: A Link Between Hypertriglyceridemia and Vascular Dysfunction?
Circ. Res.,
December 5, 2008;
103(12):
1348 - 1350.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al.
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Diabetes and Vascular Disease Research,
November 1, 2008;
5(4):
319 - 335.
[Abstract]
[PDF]
|
|
|
|
